University of Colorado

Geron Corporation

Other

University Patents, Inc.

University Technology Corporation

Competitive Technologies, Inc.

University Research Corporation

Thomas R Cech

Joachim Lingner

Toru M Nakamura

William H Andrews

Calvin B Harley

Gregg B Morin

Karen B Chapman

Arthur J Zaug

Michael D Been

Bruce A Sullenger

Bruce Sullenger

Peter H Baumann

Felicia L Murphy

Cheryl Grosshans

Daniel Herschlag

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

Method for eliciting an immune response to human telomerase reverse transcriptase

Human telomerase catalytic subunit

Kit for detection of telomerase reverse transcriptase nucleic acids

Antibody to telomerase reverse transcriptive

Human telomerase reverse transcriptase polypeptides

Increasing the proliferative capacity of cells using telomerase reverse transcriptase

The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity

Treating cancer using a telomerase vaccine

This disclosure provides TRT antisense oligonucleotides, methods of detecting TRT, methods of diagnosing telomerase-related conditions, methods of diagnosing and providing a prognosis for cancer, and methods of treating telomerase-related conditions, including cancer.

Identifying and testing antisense oligonucleotides that inhibit telomerase reverse transcriptase

The present invention is directed to monoclonal or recombinant antibodies or fragments thereof that bind to human telomerase reverse transcriptase (hTRT) protein. The present invention is also directed to methods of identifying or detecting hTRT polypeptides in biological samples. The invention is further directed to methods of generating antibodies that specifically bind to hTRT protein.

Antibody to telomerase reverse transcriptase

Nucleic acids encoding human telomerase reverse transcriptase and related homologs

The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.

Mammalian cells that have increased proliferative capacity

The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of, and related sequences fromsequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.

Telomerase

Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.

Alteration of sequence of a target molecule

Growing community of inventors

Potomac, MD, United States of America

Thomas R Cech